Monoclonal antibodies preventing leukocyte activation reduce experimental neurologic injury and enhance efficacy of thrombolytic therapy
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
We evaluated the ability of monoclonal antibodies directed against leukocyte adhesion molecules (intercellular adhesion molecule-1 [ICAM-1], CD18) to enhance the efficacy of thrombolysis in a rabbit cerebral embolism stroke model. Both tissue-type plasminogen activator (tPA) and anti-CD18 (alpha-CD18) monoclonal antibody administered 5 minutes after embolization increased the quantity of clots required to produce neurologic damage, although the combination was no more effective than either substance alone. Neither alpha-CD18 nor anti-ICAM-1 (alpha-ICAM-1) improved neurologic outcome at postischemic delays of 15 or 30 minutes. However, the combination of alpha-ICAM-1 (15 minutes after embolization) and tPA (2 hours after embolization) significantly improved neurologic outcome even though neither substance was effective alone at these postembolization delays. These findings suggest that prevention of leukocyte adhesion increases the postischemic duration at which thrombolytic therapy remains effective.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Lewy body variant of Alzheimer's disease: A clinical and pathologic entity
Hansen, L., Salmon, D., Galasko, D., Masliah, E., Katzman, R., DeTeresa, R., Thal, L., Pay, M. M., Hofstetter, R., Klauber, M., et al. (1990) · Neurology · doi:10.1212/wnl.40.1.1 · Cited by 1,068
Cited by
Mechanisms, challenges and opportunities in stroke
Lo, E. H., Dalkara, T., & Moskowitz, M. A. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1106 · Cited by 1,781
The inflammatory response in stroke
Wang, Q., Tang, X. N., & Yenari, M. A. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.014 · Cited by 1,177
Inflammatory Mediators and Stroke: New Opportunities for Novel Therapeutics
Barone, F. C., & Feuerstein, G. Z. (1999) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199908000-00001 · Cited by 930
Neuroinflammatory mechanisms of blood-brain barrier damage in ischemic stroke
Yang, C., Hawkins, K. E., Doré, S., & Candelario-Jalil, E. (2019) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00136.2018 · Cited by 871
“The identification of the deficiency of 2-integrins in humans shed light on the biological importance of these molecules in immune regulation, where deficient expression of the entire CD11/CD18 complex results in impaired immune function (3).”
BackgroundInfluentialInflammation and glial responses in ischemic brain lesions
Stoll, G. (1998) · Progress in Neurobiology · doi:10.1016/s0301-0082(98)00034-3 · Cited by 795
Inflammation after Intracerebral Hemorrhage
Wang, J., & Doré, S. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600403 · Cited by 651
Targeting Neutrophils in Ischemic Stroke: Translational Insights from Experimental Studies
Jickling, G. C., Liu, D., Ander, B. P., Stamova, B., Zhan, X., & Sharp, F. R. (2015) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2015.45 · Cited by 644
Gladstone, D. J., Black, S. E., & Hakim, A. M. (2002) · Stroke · doi:10.1161/01.str.0000025518.34157.51 · Cited by 635
Stroke and the immune system: from pathophysiology to new therapeutic strategies
Macrez, R., Ali, C., Toutirais, O., Le Mauff, B., Defer, G., Dirnagl, U., & Vivien, D. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70066-7 · Cited by 560
Use of anti-ICAM-1 therapy in ischemic stroke: Results of the Enlimomab Acute Stroke Trial
Enlimomab Acute Stroke Trial Investigators (2001) · Neurology · doi:10.1212/wnl.57.8.1428 · Cited by 544
Jurcau, A., & Simion, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010014 · Cited by 500
Leker, R. R., & Shohami, E. (2002) · Brain Research Reviews · doi:10.1016/s0165-0173(02)00157-1 · Cited by 409
Inflammatory Cell Adhesion Molecules in Ischemic Cerebrovascular Disease
Frijns, C. J. M., & Kappelle, L. J. (2002) · Stroke · doi:10.1161/01.str.0000021902.33129.69 · Cited by 390
Neuroprotection for ischemic stroke: Two decades of success and failure
Cheng, Y. D., Al-Khoury, L., & Zivin, J. A. (2004) · NeuroRX · doi:10.1602/neurorx.1.1.36 · Cited by 384
Self-citationIadecola, C., Zhang, F., Casey, R., Clark, H. B., & Ross, M. E. (1996) · Stroke · doi:10.1161/01.str.27.8.1373 · Cited by 322
Can the immune system be harnessed to repair the CNS?
Popovich, P. G., & Longbrake, E. E. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2398 · Cited by 284
Inflammatory responses in hypoxic ischemic encephalopathy
Liu, F., & Mccullough, L. D. (2013) · Acta Pharmacologica Sinica · doi:10.1038/aps.2013.89 · Cited by 283
Cell adhesion molecules and ischemic stroke
Yilmaz, G., & Granger, D. N. (2008) · Neurological Research · doi:10.1179/174313208x341085 · Cited by 276
Inflammation and Infection in Clinical Stroke
Emsley, H. C. A., & Tyrrell, P. J. (2002) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-200212000-00001 · Cited by 276
Reperfusion Injury after Focal Cerebral Ischemia: The Role Inflammation and the The rapeutic Horizon
Jean, W. C., Spellman, S. R., Nussbaum, E. S., & Low, W. C. (1998) · Neurosurgery · doi:10.1097/00006123-199812000-00076 · Cited by 264
Inflammatory Responses in Brain Ischemia
Kawabori, M., & Yenari, M. (2015) · Current Medicinal Chemistry · doi:10.2174/0929867322666150209154036 · Cited by 262
Cytokines and adhesion molecules in stroke and related diseases
Kim, J. S. (1996) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(95)00338-3 · Cited by 216
Therapeutic neutralization of CD95-ligand and TNF attenuates brain damage in stroke
Martin-Villalba, A., Hahne, M., Kleber, S., Vogel, J., Falk, W., Schenkel, J., & Krammer, P. H. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400882 · Cited by 209
“Early studies in a rabbit model of acute stroke indicated the potential of the combination of thrombolytic therapy with anti-ICAM-1 antibodies.(48) In comparison, neutralization of TNF and CD95L, not only attenuates reperfusion damage but also helps to maintain neuronal viability until reperfusion is achieved.”
BackgroundConnolly, E. S., Winfree, C. J., Prestigiacomo, C. J., Kim, S. C., Choudhri, T. F., Hoh, B. L., Naka, Y., Solomon, R. A., & Pinsky, D. J. (1997) · Circulation Research · doi:10.1161/01.res.81.3.304 · Cited by 198
Ritter, L. S., Orozco, J. A., Coull, B. M., & McDonagh, P. F. (2000) · Stroke · doi:10.1161/01.str.31.5.1153 · Cited by 197
Prestigiacomo, C. J., Kim, S. C., Connolly, E. S., Liao, H., Yan, S.-F., & Pinsky, D. J. (1999) · Stroke · doi:10.1161/01.str.30.5.1110 · Cited by 179
An Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Metadata
- Authors
- Bowes, M. P., Rothlein, R., Fagan, S. C., & Zivin, J. A.
- Venue
- Neurology
- Published
- 1995-04
- Volume
- 45
- Issue
- 4
- Pages
- 815-819
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W1991705223
- Cited by
- 196
- References
- 1
- FWCI
- 13.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.